Achira para Inflamación
Canna indica — 12 estudios científicos revisados
Moderate¿Sirve Achira para inflamación?
El extracto de las hojas muestra afinidad por receptores como el Factor de Necrosis Tumoral-alfa (TNF-α) y la Ciclooxigenasa-2 (COX-2), lo que sugiere una capacidad para modular la respuesta...
Compuestos activos involucrados: Alcaloides, Flavonoides, Glucósidos, Saponinas, Terpenos, ácido rosmarínico
Evidencia Científica
Los siguientes estudios han investigado la relación entre Achira y inflamación:
Indian Shot (Canna Indica L). Leaves Provide Valuable Insights into the Management of Inflammation and Other Associated Disorders Offering Health Benefits.
BACKGROUND: Throughout history, plants have played a crucial role in advancing medicinal treatments by providing a diverse range of compounds for the development of innovative therapies. Canna indica L. a tropical herb of the Cannaceae family, also known as Indian shot, has a rich history of traditional use in treating ailments like inflammation, malaria, dysentery, fever, dropsy, and diarrhea. OBJECTIVE: This comprehensive research invesigates the extract preparation of C. indica leaves using multidisciplinary analytical approaches for this extract in order to shed light on its therapeutic po
PubMed: 39677290Canna indica L. attenuates high-glucose- and lipopolysaccharide-induced inflammatory mediators in monocyte/macrophage.
ETHNOPHARMACOLOGICAL RELEVANCE: Canna indica L. (CI) has been widely used as a folklore medicine in tropical and subtropical areas with beneficial effects in numerous diseases, including infection, rheumatism, hepatitis, and it has also been identified as an antioxidant. MATERIALS AND METHODS: The present study aimed to investigate the effect of Canna indica CI ethanolic extract (CIE) on productions of nitric oxide (NO), prostaglandin E2 (PGE2), and interleukin-1β (IL-1β) in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. In addition, the effects of CIE in high glucose (HG)-induced U93
PubMed: 23639363The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
OBJECTIVE: Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that can develop in most inflammatory contexts. They can progress rapidly, and early identification and management are critical for preventing organ failure and mortality. This effort aimed to develop evidence-based and consensus-based points to consider to assist clinicians in optimising decision-making in the METHODS: A multinational, multidisciplinary task force of physician experts, including adult and paediatric rheumatologists, haematolo
PubMed: 37487610Biological and clinical roles of IL-18 in inflammatory diseases.
Several new discoveries have revived interest in the pathogenic potential and possible clinical roles of IL-18. IL-18 is an IL-1 family cytokine with potent ability to induce IFNγ production. However, basic investigations and now clinical observations suggest a more complex picture. Unique aspects of IL-18 biology at the levels of transcription, activation, secretion, neutralization, receptor distribution and signalling help to explain its pleiotropic roles in mucosal and systemic inflammation. Blood biomarker studies reveal a cytokine for which profound elevation, associated with detectable '
PubMed: 38081945The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).
OBJECTIVE: Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that can develop in most inflammatory contexts. They can progress rapidly, and early identification and management are critical for preventing organ failure and mortality. This effort aimed to develop evidence-based and consensus-based points to consider to assist clinicians in optimising decision-making in the early stages of diagnosis, treatment and monitoring of HLH/MAS. METHODS: A multinational, multidisciplinary task force of physician exp
PubMed: 37486733Seguridad y Precauciones
La seguridad en el uso de Achira (Canna indica) requiere una evaluación cuidadosa debido a la presencia de diversos metabolitos secundarios como alcaloides, saponinas y glucósidos. En cuanto al embarazo y la lactancia, no existen estudios clínicos exhaustivos en humanos que determinen la seguridad del consumo de extractos concentrados de Canna indica; por lo tanto, se recomienda evitar su uso terapéutico en estas etapas para prevenir posibles efectos teratogénicos o alteraciones en la composición de la leche materna, dada la falta de evidencia sobre la transferencia placentaria o transmamaria de sus compuestos activos. Para niños menores de 12 años, la administración de extractos debe ser estrictamente supervisada por un profesional de la salud, ya que sus sistemas metabólicos están en desarrollo y la toxicidad potencial de las saponinas o alcaloides podría ser mayor en organismos pediátricos. Respecto a las interacciones farmacológicas, se debe tener precaución con la warfarina, debido a que los compuestos antioxidantes y flavonoides de la planta podrían alterar la actividad de los procesos de coagulación, modificando la eficacia del fármaco. Con la metformina, la interacción podría manifestarse a través de la modulación de la respuesta glucémica, lo que requiere monitoreo de niveles de glucosa. En el caso de antihipertensivos, la planta podría potenciar o interferir con la regulación de la presión arterial mediante mecanismos de acción en receptores vasculares no totalmente caracterizados.
Otras plantas estudiadas para Inflamación
Perfil completo: Ver todos los usos y evidencia de Achira →